Illumina Appoints Joydeep Goswami Chief Financial Officer

Rhea-AI Summary

Illumina, Inc. (NASDAQ: ILMN) has appointed Joydeep Goswami as Chief Financial Officer, effective immediately. Previously serving as Chief Strategy and Corporate Development Officer and interim CFO since July 2022, Goswami's new role will involve overseeing financial planning, analysis, accounting, and investor relations. With over 20 years of experience in the life sciences industry, he aims to enhance shareholder value through improved financial operations. Francis deSouza, CEO of Illumina, expressed confidence in Goswami’s ability to drive growth, supported by a strong finance team.

Positive

• Joydeep Goswami's appointment as CFO brings strategic expertise and experience from previous roles.
• Goswami has a strong background in financial operations and corporate development, potentially enhancing long-term shareholder value.

Negative

• None.

SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately. Goswami previously served as Illumina's Chief Strategy and Corporate Development Officer and interim Chief Financial Officer. As CFO, Goswami will be responsible for the Company's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. He will also continue to lead the corporate development and strategic planning function.

"Joydeep's strategic expertise, deep industry knowledge, and extensive global business experience make him ideally positioned to help lead the next phase of Illumina's growth," said Francis deSouza, Illumina's Chief Executive Officer. "Joydeep is a proven and disciplined leader with a strong track record of creating value and building high-performing teams."

Goswami assumed all CFO responsibilities on an interim basis in July 2022 and has served as Chief Strategy and Corporate Development Officer since 2019. In that role, Goswami was responsible for driving planning, strategic partnerships and acquisitions and worked closely with the Finance organization on capital allocation, financial planning, and deal execution.

"As CFO, I look forward to helping maximize long-term shareholder value by scaling our financial operations, analytics and forecasting capabilities," said Goswami. "Working closely with the entire leadership team and our world-class finance organization, we'll continue to deliver on Illumina's mission to improve human health by unlocking the power of the genome."

With more than 20 years of experience in the life sciences industry, Goswami has held various senior and international management roles with P&L responsibility. Prior to joining Illumina, he was President, Clinical Next Generation Sequencing (NGS) and Oncology at Thermo Fisher Scientific, where he led the expanded application of NGS across clinical oncology, research, and reproductive health segments. While at Thermo Fisher, he also served as President, Asia Pacific and Japan leading the integration of Life Technologies APJ business into the regional Thermo Fisher organization, doubling organic growth while significantly improving the profitability of the business. Earlier in his career, Goswami was President, Japan at Life Technologies where he drove strong top and bottom-line growth through key customer engagement. Goswami began his career at McKinsey & Company, where he managed projects and teams serving global clients spanning several industries including pharmaceuticals, medical products, chemical, private equity and technology.

Goswami holds an M.S., Ph.D. in chemical engineering, and an MBA from the Massachusetts Institute of Technology, as well as a bachelor's degree in chemical engineering from the Indian Institute of Technology, Mumbai.

"We have full confidence in Joydeep and his ability to drive continued growth and profitability in partnership with Illumina's already strong finance leadership team," said Caroline Dorsa, Illumina Board member and Chair of the Audit Committee. "From my own experience, I know how important it is to have a financial leader who brings both a strategic and operational mindset to creating shareholder value. Coming from his role as Chief Strategy and Corporate Development Officer, Joydeep brings a unique understanding of the genomics industry that is critical for success."

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Investors:
Salli Schwartz
858.291.6421
IR@illumina.com

Media:
David McAlpine
347-327-1336
PR@illumina.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-joydeep-goswami-chief-financial-officer-301736138.html

SOURCE Illumina, Inc.

FAQ

Who is the new CFO of Illumina?

Joydeep Goswami has been appointed as the new Chief Financial Officer of Illumina.

When did Joydeep Goswami become the CFO of Illumina?

Joydeep Goswami was appointed Chief Financial Officer effective February 1, 2023.

What was Joydeep Goswami's role before becoming CFO?

Before becoming CFO, Goswami served as Chief Strategy and Corporate Development Officer at Illumina.

What are Joydeep Goswami's responsibilities as CFO?

As CFO, Goswami will oversee financial planning, analysis, accounting, investor relations, internal audit, tax, and treasury functions.

How might Joydeep Goswami's appointment impact Illumina?

Goswami's strategic expertise may lead to enhanced financial operations and increased shareholder value for Illumina.